Accelerated CMC workflows to enable speed to clinic in the COVID-19 era: A multi-company view from the biopharmaceutical industry.
- DOI
- 10.1002/btpr.3321
- Published
- 2023 Mar
- Container
- Biotechnology progress
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/btpr.3321,
title = {Accelerated CMC workflows to enable speed to clinic in the COVID-19 era: A multi-company view from the biopharmaceutical industry.},
author = {Higgins MF and Abu-Absi N and Gontarz E and Gorr IH and Kaiser K and Patel P and Ritacco F and Sheehy P and Thangaraj B and Gill T},
year = {2023},
journal = {Biotechnology progress},
doi = {10.1002/btpr.3321},
url = {https://doi.org/10.1002/btpr.3321}
}RIS
TY - JOUR TI - Accelerated CMC workflows to enable speed to clinic in the COVID-19 era: A multi-company view from the biopharmaceutical industry. AU - Higgins MF AU - Abu-Absi N AU - Gontarz E AU - Gorr IH AU - Kaiser K AU - Patel P AU - Ritacco F AU - Sheehy P AU - Thangaraj B AU - Gill T PY - 2023 JO - Biotechnology progress DO - 10.1002/btpr.3321 UR - https://doi.org/10.1002/btpr.3321 ER -
APA
MF, H., N, A., E, G., IH, G., K, K., P, P., F, R., P, S., B, T., & T, G. (2023). Accelerated CMC workflows to enable speed to clinic in the COVID-19 era: A multi-company view from the biopharmaceutical industry.. Biotechnology progress. https://doi.org/10.1002/btpr.3321
Source records
- pubmed · retrieved 2026-09-26T09:33:47.718Z